3'-Sialyllactose |
| رقم الكتالوجGC70284 |
3'-Sialyllactose (3'-SL) هو بريبيوتيك، يحافظ على استتباب المناعة ويمارس تأثيرات مضادة للالتهابات ومضادة لالتهاب المفاصل.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 35890-38-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
3'-Sialyllactose (0-250 μM; 24-36 h) promotes and restores Col2a1 synthesis and accumulates extracellular sulphated proteoglycan, and inhibits the effect of inflammatory cytokines[1].
3'-Sialyllactose (0-250 μM; 24 h) activates the expression of Sox9 and inhibits NF-κB activation in chondrocytes[1].
3'-Sialyllactose (0-5000 μg/plate) shows no mutagenic effect with no evident growth inhibition and deposition in all strains in the presence or absence of metabolic activation[3].
3'-Sialyllactose (1250 μg/mL) induces no chromosomal aberrations and shows non-clastogenic effect in either the presence or absence of metabolic activation[3].
3'-Sialyllactose (10-100 mg/kg; p.o. three times a week for 6 weeks) protects mice against cartilage destruction from osteoarthritis[1].
3'-Sialyllactose (500, 1000 and 2000 mg/kg; orally administration; once) induces no micronuclei in the bone marrow cells of mice[3].
3'-Sialyllactose (oral administration; (500 to 1000 to 2000 mg/kg) every dose at 4-day intervals) shows the maximum tolerance dose (MTD) is greater than 2000 mg/kg in male and female beagle dogs[3].
3'-Sialyllactose shows a lethal dose (LD50) above 20 g/kg bw, the highest dose tested[3].
References:
[1]. Jeon J, et al. 3'-Sialyllactose protects against osteoarthritic development by facilitating cartilage homeostasis. J Cell Mol Med. 2018 Jan;22(1):57-66.
[2]. Kang LJ, et al. 3'-Sialyllactose prebiotics prevents skin inflammation via regulatory T cell differentiation in atopic dermatitis mouse models. Sci Rep. 2020 Mar 27;10(1):5603.
[3]. Kim D, et al. Toxicological evaluation of 3'-sialyllactose sodium salt. Regul Toxicol Pharmacol. 2018 Apr;94:83-90.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *